Rchr
J-GLOBAL ID：202001012118477981
Update date: Oct. 04, 2024
TAKAKO KANEYASU
カネヤス タカコ | TAKAKO KANEYASU
Affiliation and department：
Job title：
Assistant Professor
Research field (3)：
Healthcare management, medical sociology
, Metabolism and endocrinology
, Medical equipment testing
Research keywords (1)：
Pharmacoeconomics, Health technology assessment, patient-reported outcome, diabetes
Research theme for competitive and other funds (3)：
- 2021 - 2026 Patient and public involvement in health technology assessment:
- 2020 - 2024 Development of the new healthcare decision support system integrating multiple value-based criteria including cost-effectiveness
- 2020 - 2023 わが国の糖尿病治療医療経済評価モデルの確立-神経障害関連QOL・PRO評価の応用
Papers (11)：
-
Takako Kaneyasu, Kaoru Ito, Kojiro Shimozuma. Scoping Review of Cost-Effectiveness Analysis of Pharmacotherapy for Painful Diabetic Neuropathy -Implications for Studies in Japan. Japanese Journal of Pharmaceutical and Diabetes. 2024. 13. 2
-
Kaneyasu T, Hoshino E, Naito M, Suzukamo Y, Miyazaki K, Kojima S, Yamaguchi T, Kawaguchi T, Miyaji T, Nakajima TE, et al. How to select and understand guidelines for patient-reported outcomes: a scoping review of existing guidance. BMC health services research. 2024. 24. 334
-
Kaneyasu T, Saito S, Miyazaki K, Suzukamo Y, Naito M, Kawaguchi T, Nakajima TE, Yamaguchi T, Shimozuma K. Perceptions regarding the concept and definition of patient-reported outcomes among healthcare stakeholders in Japan with relation to quality of life: a cross-sectional study. Health and quality of life outcomes. 2024. 22. 8
-
[Translation into Japanese] COSMIN guideline for systematic reviews of patient-reported outcome measures. Jpn Pharmacol Ther. 2023. 51. 2. 177-189
-
[Translation into Japanese] Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Jpn Pharmacol Ther. 2023. 51. 1. 31-45
ｍore...
Books (2)：
-
QOL・PRO評価 指南-概念・測定・解釈から臨床応用まで-
ライフサイエンス出版 2024
-
患者報告アウトカム(PRO)使用についてのガイダンス集
https://www.lifescience.co.jp/pro/ 2023
Lectures and oral presentations (7)：
-
The Role and Implementation of Patient and Public Involvement in Health Technology Assessment: A Systematic Search and Implications for Japan
(International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 2024)
-
Cost-effectiveness of preventive intervention for prediabetes in Japan
(ISPOR Europe 2021 2021)
-
日本におけるがん薬物療法の医療経済評価報告の現状-有害事象管理の観点から-
(第 59 回日本医療・病院管理学会学術総会 2021)
-
Differences in the conceptual structures perceived by stakeholders in Japan between "patient-reported outcomes" and "quality of life."
(ISOQOL 28th Annual Conference 2021)
-
糖尿病神経障害に対する薬物療法の費用効果分析のシステマ ティックレビュー.
(第9 回日本くすりと糖尿病学会学術集会 2021)
ｍore...
Education (4)：
- - 2020 International University of Health and Welfare Graduate School of Pharmacy Doctor’s Program in Medical and Biopharmaceutical Science
- - 2016 International University of Health and Welfare Graduate School of Pharmaceutical Science Master’s Program in Biopharmaceutical Science
- - 2011 Keio University (Correspondence School) Faculty of Economics
- - 1990 Meiji Pharmaceutical University Faculty of Pharmacy Pharmaceutical Chemistry
Professional career (2)：
- Master of Pharmaceutical Sciences. (International University of Health and Welfare)
- Doctor of Pharmacy (International University of Health and Welfare)
Association Membership(s) (4)：
ISPOR日本部会
, International Society for Pharmacoeconomics and Outcome Research
, the Asia Association for the Study of Diabetes
, Japan Pharmaceutical and Diabetes Society
